The Latest Approaches in the Evaluation of Drugs that Affect Heart Rate, Blood Pressure, QT Prolongation and Other CV Safety Related Issues.
Conference Co-chairs: Dr. Daniel Bloomfield (CSRC Executive Committee) and Dr. Lawrence Satin (CSRC Membership Committee)
Click here to view the brochure.
- Review the various benefits available by analyzing continuous electrocardiographic recordings in early exploratory development
- Prevent catastrophic late stage failures, reduce the total cost of cardiac safety assessment programs and avoid TQT studies in the late stages of development
- Gain a regulatory perspective on cardiac safety assessments for
oncology therapies
- Hear about the new FDA guidance in evaluating cardiovascular risk in new anti-diabetic therapies
- Explore how to analyze and interpret data from cardiovascular safety studies using more standardized and consistent methods
- Examine drugs that affect heart rate and explore strategies involved in evaluating their overall cardiac safety liability
- Review the diverse therapeutic approaches for treating patients with atrial fibrillation
- Learn how S-troponins can be used as a screening tool in early clinical development